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Abstract
Alcohol dehydrogenase inhibitors may be employed for the treatment of parasitic infection
in humans. A series of substituted pyrazoline derivatives were synthesized to elucidate the
pharmacophore for the inhibition of ADH. Targeted structure modification was used to
alter the electronic and steric interactions associated with the enzyme active site. This
study identified several effective N-aryl-carboxamide derivatives with horse liver ADH
inhibition, comparable to that of 4-methylpyrazole, a known ADH inhibitor. The
identification of pharmacophoric regions will allow for the methodological modification of
these compounds to improve enzyme affinity and targeted inhibition. Future research may
include additional solubility, toxicity and docking analysis of these compounds.
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Chapter 1: Introduction
1.1: Introduction
Alcohol dehydrogenase (ADH) enzymes, present in both prokaryotes and eukaryotes, are
responsible for alcohol metabolism and rely upon the reversible conversion between
NADH (nicotinamide adenine dinucleotide) and NAD+ for anaerobic metabolism
(Scheme 1). Alcohol dehydrogenases are essential for the growth and survival of many
bacteria and eukaryotic parasites through fermentation metabolism. In humans, alcohol
dehydrogenases are required for the breakdown of alcohol into acetaldehyde and acetate.1
Humans possess several enzymes capable of metabolizing alcohol through oxidative
(alcohol dehydrogenase, cytochrome P450 isoxymes, and catalase) and non-oxidative
pathways (fatty acid ethyl ester synthase and phospholipase D)1. As ADHs are present
but nonessential in humans, therapeutics can be designed to inhibit anaerobic parasite
metabolism via ethanol fermentation.

Scheme 1. Interconversion between alcohol and aldehyde by alcohol dehydrogenases.

Drug design relies heavily upon the identification of highly effective compounds with
low toxicity in humans. Enzyme inhibitors are designed specifically to optimize binding
efficiency at the active site of a target enzyme often of medicinal or therapeutic interest.
An understanding of the enzyme active site characteristics may allow for optimization of
cooperative interactions, thus increasing binding efficiency and enzyme inhibition.

1

Protein amino acid sequences, crystal structures, and modeling software are commonly
used to understand likely binding interactions with target molecules. Most effective
inhibitors will have a low inhibitory concentration (Ki)a required to significantly decrease
function. At these low concentrations, the inhibitory compounds ought to have low
toxicity as well. Inhibitors are commonly screened for drug properties including toxicity,
carcinogenicity, and metabolic stability with LD50b, AMES (mutagenic potential
determination), and LC-MS serum monitoring assays.

Fomepizole, 4-methylpyrazole (Figure 1), is an effective ADH inhibitor (Ki of 0.013 μM
for horse liver ADH)2 and subsequent structural modifications have been done to assess it
as an anti-parasitic and anti-inflammatory agent3–5. This compound has been used as a
therapeutic agent for the treatment of methanol poisoning since 19973–5. 4Methylpyrazole exhibits an ADH binding affinity greater than 8,000 times that of ethanol
with no significant toxicity identified at concentrations required for methanol poisoning
treatment6. The effectiveness of this small substructure has sparked interest in other
nitrogen heterocycles, such as pyrazolines.

N

NH

Figure 1. 4-Methylpyrazole

a

The Inhibitor constant (Ki) of a compound is equal to the concentration of inhibitor that results in half
maximal inhibition. Low Ki values are associated with effective inhibitors and stronger binding affinity.
b
The LC50 for pharmaceuticals is equivalent to the treatment dose required for death in 50% of subjects.
This value is directly correlated with drug toxicity.

2

Several pyrazoline and triazole derivatives are currently under investigation as
therapeutic agents for inflammation, tumor suppression, and parasitic infection
management7–12. Pyrrole and pyrazoles are the structural units for many natural products,
including withasomnine and pyrazomycin (Figure 2)10,13,14. Pyrazomycin, (pyrazofurin),
was isolated as a fermentation product of Streptomyces candidus and has proven to be an
extremely effective monophosphate decarboxylase inhibitor (Ki 5.0 nM)10. The diverse
applications of these derivatives in current pharmaceutics also indicates that these may be
effective as inhibitors for a wide range of enzyme families including monoamine
oxidases, NADPH oxidases, ipoxygenases and cyclooxygenases15–17.

Figure 2. “Withasomnine” (3-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole) and
“Pyrazomycin” ((1S)-1,4-Anhydro-1-(5-carbamoyl-4-hydroxy-1H-pyrazol-3-yl)-Dribitol).

Pyrazoline derivatives specifically have been identified as effective anti-tubercular
agents, which provide an alternative approach for the treatment of multi-drug resistant
infections18. Additionally, several 1,3-disubstituted, 1,3,4-trisubstituted, and 1,3,5trisubstituted pyrazolines have been identified as successful inhibitors of anaerobic
growth in the parasitic protist Entamoeba histolytica. The mode of inhibition by these
compounds has yet to be elucidated8,19–21.

3

The thiocarbamoyl substituent (adjacent to the pyrazoline) may potentially be the
pharmacophore for these molecules22. Carbamates and thiocarbamates have been shown
to provide significant anti-fungal, anti-cancer, and anti-protozoal properties22–24.
Thiocarbamoyl derivatives have exhibited an increased efficiency, relative to carbamoyl
derivatives for E. histolytica trophozoite growth inhibition, which relies upon ADH
function (EhADH2) for anaerobic growth and survival25–28. It is presumed that inhibition
of the alcohol dehydrogenase function of this bifunctional enzyme will eliminate
trophozoite growth.

The current treatment for E. histolytica infection is the antiprotozoal drug metronidazole.
Metronidazole acts as a DNA replication inhibitor and has been proven to be effective for
E. histolytica growth inhibition at an IC50c value of 9.5 μM (Figure 3)7,25,27. This
treatment is associated with significant neural toxicity and morbidity. As such, alternative
treatments are desirable. The identification of alternative treatments for parasitic and
bacterial infections are also necessary as current treatments are toxic and drug resistance
is increasing.

Figure 3. “Metronidazole”, 2-methyl-5-nitroimidazole-1-ethanol.

c

The IC50 value of a compound is equivalent to the concentration required to reduce substrate binding by
50%. Low IC50 values are associated with strong competitive inhibitors.

4

As ADH is nonessential to human health, the identification of effective ADH inhibitors
may allow for the improved treatment of several bacterial and parasitic infections25,28,29.
Additionally, the identification of pharmacophoric regions of substituted pyrazolines may
allow for the targeted modification of known inhibitors for improved function and more
effective drug treatments. Therefore, this research project may be directly applied to drug
screening and subsequent pharmaceutical development.

The compounds synthesized in this study will be evaluated for their inhibitory efficiency
in order to determine alternative therapeutic target scaffolds for the management of
bacterial and parasitic infection. A goal of this study is to identify pyrazoline inhibitors
with inhibition comparable to or better than that of 4-methylpyrazole. The identification
of the potential pharmacophoric regions of substituted pyrazoline and/or pyrazole
derivatives may then allow for further methodological modification for improved ADH
affinity and targeted inhibition.

Figure 4. 1,3-diaryl substituted carbamoyl pyrazoline structure.

We propose to probe the carbamoyl pyrazoline structure through modification of regions
A, B, and C (Figure 4). Rings A and C will be modified through the investigation of aryl
substituents with varied electron donating and withdrawing properties, as well as
modifying the aryl ring to alkyl groups. The pyrazoline heterocycle, B, will also be

5

investigated through oxidation and reduction. The importance of the carbamoyl region
will be investigated with elimination of the carbonyl and nitrogen of the carbamoyl
group. Additionally, alkylation of the secondary nitrogen will be explored. These
structure-activity investigations ought to then elucidate the structural requirements for
alcohol dehydrogenase inhibition.

Synthesized inhibitors will be screened as inhibitors of horse liver ADH. Enzyme
activity, converting aldehyde to alcohol with NADH as a co-factor, will be monitored.
(This is the reaction direction required for fermentative metabolism in many anaerobic
pathogens.) Successful inhibitors will be those that significantly decrease the observed
enzyme activity monitored through a change in absorbance at 340 nm resulting from the
conversion of the coenzyme NADH to NAD+ (Scheme 1). The assessment of a
compound’s inhibition activity will be relative to that of the blank, which contains all
components of the assay except the proposed inhibitor compound.

Horse liver ADH was selected for all enzyme assays and modeling studies. Horse liver
ADH is commonly used to model human ADH as it is homologous to the structure of
human ADH at its active site. This enzyme is a eukaryotic ADH, which resembles the
tertiary structure of many parasitic ADHs. Additionally, this enzyme is a zinc
metalloenzyme requiring the coordination of two zinc cations for enzymatic activity30.
The two zinc cations are tetracoordinated at the active site with two cysteines, a histidine,
and one water molecule30. The substrates for horse liver ADH include benzaldehyde,
acetaldehyde, ethanol, and benzyl alcohol31. Horse liver ADH also requires

6

NADH/NAD+ as a cofactor for activity. NADH binds to an NADH binding domain
before substrate coordinates/binds, thus closing the active site to its active form30. A
methionine residue (position 141) buried in the active site pocket of human ADH is
known to play an essential role in substrate binding as well as binding 4-methylpyrazole,
a known ADH inhibitor3. This methionine residue lines the substrate binding pocket near
the docking site of the methyl group of 4-methylpyrazole3. Horse liver ADH used in this
study lacks methionine at the substrate binding region but other hydrophobic amino acids
line the substrate binding site which may engage in similar interactions (Valine52,53,58,63, Glycine-55,66, Leucine-57,61, Proline-60,62, Isoleucine-64, Alanine-65)31.

The positive inhibition control compound within this study will be 4-methylpyrazole
(Figure 1)2,5,32. This compound has previously been identified as a competitive inhibitor
of alcohol dehydrogenases (Ki 0.013 μM for horse liver ADH) and our reported
experimental enzymatic inhibition activity will be in relation to this this known value2.
Enzyme assays will be performed with no pyrazoline inhibitor present as a positive
control to ensure that the enzyme is functional under the given conditions. Additionally,
control assays will be performed in the presence of NADH and inhibitor (without
enzyme) to determine if there is any interaction between the pyrazoline compounds and
NADH coenzyme that would perturb the spectrophotometric data analysis.

1.2: Synthesis
The reactions central to the synthetic efforts of this project are outlined below. The
synthesis of 3-aryl 2-pyrazolines was required for all described herein. Substituents on

7

rings A and C were assessed in the para position for all derivatives to maximize the
impact of the net electronic dipole of the aryl ring. The para substituent modifications
focus upon the role of electron density within the ring (electron donating or withdrawing
groups) rather than steric factors. Varied substituents at the meta position would likely
target mainly inductive influences while the ortho position would likely target a
substituent- dependent combination of electronic and steric influences.

1.2.1: Modification of Ring A:
In order to assess the role of the A ring, para substituents of varied electron
donating or withdrawing character were synthesized and evaluated for their ADH
inhibition (Scheme 2). Additionally, the influence of electronic and steric
hindrance upon ADH inhibition at this pyrazoline position was assessed with a
methyl group at this position in place of the 3-aryl group.

Scheme 2. Synthesis of 3-aryl 2-pyrazoline. Modifications of ring A including
para substituents.

1.2.2: Modification of Ring B:
In order to assess the role of ring B, the pyrazoline ring, it will be either reduced
or oxidized (Scheme 3 and Scheme 4, respectively). These modifications will
affect most directly the electronic structure of the compounds, and minimally
steric considerations.

8

Scheme 3. Synthetic route to oxidize 1 to form 3-(4-chlorophenyl)-1(phenylthiocarbamoyl)-2-pyrazole 2.

Oxidation of pyrazoline 1 to pyrazole 2 has been successfully performed and will
be used to evaluate the effects of increased electron density at ring B (Scheme
3)18. This transformation decreases the net dipole of the molecule and adds
additional aromatic character to the molecule. This transformation alters proposed
hydrogen bonding and stacking interactions the compounds may have within the
enzyme active site.

Scheme 4. Reduction of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
3 to N,3-diphenylpyrazolidine-1-carboxamide 4.

Reduction of pyrazoline 3 via Superhydride (lithium triethylborohydride) to
pyrazolidine 4 (Scheme 4) probes the effects of decreased electron density at the
pyrazoline position. This modification also shortens the overall conjugated system
within the molecule. This modification thus would aid in the identification of the
essential elements of the pyrazoline moiety for enzyme binding and inhibition.

9

1.2.3: Modification of Ring C:
In order to assess the role of ring C ring in ADH inhibition, a series of derivatives
with para substituents of varied electron donating/withdrawing character were
prepared (Scheme 5). Additionally, several N-propyl derivatives were synthesized
to evaluate the importance and role aromatic character at this position may have
upon ADH inhibition.

Scheme 5. Synthesis of 1,3-diaryl carbamoyl 2-pyrazoline with varied
substituents on the C ring.

1.2.4: Modification of the carbamoyl region:
In order to assess the role of electronics at the carbamoyl region on ADH
inhibition, several carbamoyl and thiocarbamoyl derivatives were synthesized
(Scheme 6). The net dipole difference between carbamoyl and thiocarbamoyl
derivatives probes primarily the role of electronics at this position. Additionally,
an amide derivative was prepared to probe the role of the carbamoyl group upon
ADH inhibition (Scheme 7). Alkylation of the carbamoyl or thiocarbamoyl region
was also investigated to understand the role of a large net dipole at this position,
and to a lesser extent steric considerations (Scheme 8, Scheme 9).

10

Scheme 6. Synthesis of 1,3-diaryl carbamoyl/thiocarbamoyl derivatives.

Scheme 7. Synthesis of compound 6, 1-(3-phenyl-4,5-dihydro-1H-pyrazol-1yl)butan-1-one.

Scheme 8. Synthesis of compound 9, N-methyl-3-phenyl-N-propyl-4,5-dihydro1H-pyrazole-1-carboxamide.

Scheme 9. Synthesis of compound 11, (1Z)‐1‐(methylsulfanyl)‐N‐propyl‐1‐(3‐ 4‐
chlorophenyl‐4,5‐dihydro-1H-pyrazol-1-yl)methanimine.

1.3: AutoDock Visualization
AutoDock modeling software will be employed in this study to visualize potential
binding modes for 1,3-disubstituted 2-pyrazolines with the horse liver ADH crystal
structure. AutoDock is an open source, three-dimensional modeling software that is
commonly employed for ligand docking analysis and protein visualization33. AutoDock

11

was selected over other modeling programs because it is an open source software with
user interface that does not require coding and it is a common method for calculating
various protein-ligand docking interactions (where ligand may be substrate, cofactor,
inhibitor, or activator)33. This program performs a series of Lamarckian genetic
algorithms to determine likely binding configurations based upon approximations of
favorable ligand docking interactions33.

Scheme 10 Synthesis of compound 1, 3-(4-chlorophenyl)-1-(phenylthiocarbamoyl)-2pyrazoline.

Compound 1 has been successfully synthesized and used for the evaluation of inhibitory
ability of 1,3-disubstituted 2-pyrazoline against ADH (Scheme 10). This compound was
selected for AutoDock modeling as it was the only completed compound at the time of
modeling analysis.

The protein crystal structure of horse liver ADH was utilized to mathematically compute
one possible enzyme conformation and inhibitor binding site, based upon common
ligand-binding interactions (PDB 1HLD) (Figure 5)31. The crystal structure of the
synthesized pyrazoline compounds are unknown and solvent influences may further alter

12

the conformation of horse liver ADH in screening assays. This analysis is thus an
estimate utilized to visualize potential binding sites. Experimental data will be used to
determine modes of inhibition and to evaluate inhibitor efficiency.

Figure 5. Crystal structure of horse liver ADH with NADH and benzyl alcohol bound
(PDB 1HLD) used for all AutoDock visualization in this study31.

The pyrazoline 1 structure was evaluated with AutoDock software to visualize a likely
mode of binding to the horse liver ADH-NADH-benzyl alcohol complex (PDB 1HLD,
Protein Data Bank ID 4XD2, the same enzyme complex proposed for kinetics assays).
Additional studies would be required to determine the most likely binding modes for
other synthesized compounds with the horse liver ADH crystal structure.

13

1.4: Description of Project
The overall goal of the studies described herein has been to elucidate structural attributes
responsible for pyrazoline-based inhibition of alcohol dehydrogenases. This aim will be
accomplished through the synthesis of 1,3-disubstituted carbamoyl- 2-pyrazoline
derivatives. Targeted and systematic structural modifications will be used to probe the
pharmacophoric region of 1,3-diaryl pyrazoline carbamates by assessing enzyme activity
in response to these structural and electronic changes. The steric and electronic influences
of the pyrazoline structure upon bioactivity will be assessed through the systematic
alteration of each of the three rings (Figure 4). Electronics are anticipated to play a
significant role with the binding and coordination of these molecule with the enzyme
complex or active site22. The thionyl and pyrazoline regions are proposed to play an
essential role in binding efficiency due to the highly electrophilic character of the ADH
binding domain31. Modification of the electronics and sterics at these positions ought to
allow for the identification of essential structural components for optimal ADH binding.

14

Chapter 2: Research Methods and Procedures
2.1: Materials and Methods
All reagents used for this study were purchased from Sigma Aldrich or Alfa Aesar and
were used in their commercial state without further purification. Concentrations of
reagents used were as follows, unless otherwise indicated: hydrazine hydrate (60%
reagent grade), absolute ethanol, and paraformaldehyde (95% reagent grade, powder).
The derivatives were characterized using 1H NMR, 13C NMR, FT-IR spectroscopy, UVVis spectroscopy, and/or melting point analysis. All NMR measurements were recorded
using a JEOL EXQ 300 MHz FT-NMR Spectrometer. Deuterated solvents used for NMR
were sourced from Sigma Aldrich and ampules were used for samples analyzed in dmsod6. All IR measurements were recorded using a Perkin Elmer Spectrum Two FT-Infrared
Spectroscopy instrument. A BUCHI M-565 melting point instrument was used for all
melting point analysis. Abbreviations used for common solvents and reagents include
dimethylsulfoxide (DMSO), tetrahydrofuran (THF), dimethylformamide (DMF),
nicotinamide adenine dinucleotide (NAD+), nicotinamide adenine dinucleotide reduced
disodium salt (NADH), and dimethylamine (DMA).

IUPAC refers to the common 2-pyrazoline structure as 4,5-dihydro-1H-pyrazole. The
common nomenclature will be used henceforth in this study.

2.1.1: Modification of Ring A:20
All derivatives probing the influence of ring A on ADH inhibition were
synthesized as described (Table 1, Scheme 3, Scheme 5). Phenone (83 mmol, 1

15

equiv.), dimethylamine hydrochloride (108 mmol, 1.3 equiv.), and
paraformaldehyde (108 mmol, 1.3 equiv.), and four drops of 0.4 M hydrochloric
acid was refluxed in a stirred solution of 13.5 mL ethanol. This solution was
cooled after 1.5 hours and 100 mL of acetone was added. The resulting solid was
washed and vacuum dried. A warm solution of 26.4 mL methanol and this
product was added over 10 minutes to a solution of 5 mL hydrazine hydrate and
2.70 mL 50% sodium hydroxide in 6.70 mL methanol. This solution was refluxed
for 45 minutes after which the methanol was evaporated under reduced pressure
to yield the product as an oil. This product (12.0 mmol, 1.00 equiv.) was
dissolved in 40.0 mL dry ether with three drops of triethylamine and isocyanate
(12.0 mmol, 1.00 equiv.). This solution was stirred for three days at room
temperature and the resulting solid was filtered and vacuum dried.

Table 1. Synthesis of derivatives with modifications of the ring A position.

Compound #

R

Z

Yield

3
12
13
14
15

H
H
p-chlorophenyl
p-methoxyphenyl
p-tolyl

O
S
O
O
O

42.8%
54.5%
40.0%
32.0%
58.0%

16
17
1

p-fluorophenyl
CH3
p-chlorophenyl

O

97.0%

O
S

69.0%
39.0%

16

2.1.2: Modification of Ring B:18
All derivatives probing the influence of oxidation of ring B were prepared as
described (Scheme 11). Pyrazoline 13 (0.079 mmol, 0.025 g, 1.0 equiv.) and an
iodine crystal (0.0373 g) was dissolved in 0.50 mL of DMSO18. This solution was
refluxed for two hours before cooling to ambient temperature. A thick paste
resulted with an orange-brown liquid supernatant. The liquid was decanted and
the solid was washed twice with aqueous 10% sodium thiosulfate. The washes
were combined with the decanted liquid. Ethanol (2 mL) was added with two
drops of 0.60 M acetic acid resulting in the precipitation of black solid. The
supernatant was decanted, and a small quantity of ice was added to the
supernatant which induced immediate precipitation.

Scheme 11. Oxidation of compound 1, 1,3-disubstituted thiocarbamoyl 2pyrazoline to compound 2, 1,3-disubstituted thiocarbamoyl pyrazole.

The reduction of ring B was attempted several times without isolation of the
desired pyrazolidine product (Scheme 12). A Schlenck flask was oven and flame
dried and pyrazoline was desiccated. Pyrazoline (0.21 mmol, 0.08 g, 1.00 equiv.)
and 6 mL anhydrous THF were added and three cycles of freeze-pump-thaw were
performed (liquid nitrogen and ethanol bath). The solution was warmed to 0 °C
and Superhydride (0.51 mmol, 0.52 mL, 2.50 equiv.) was added dropwise12.
This solution was stirred two hours at 0 °C before quenching with 2 M NaOH (2.5
17

mL) slowly. The resulting liquid was concentrated, washed with 2 M NaOH, and
back extracted in DCM. The organic layer was dried over magnesium sulfate and
concentrated. Starting pyrazoline reactant was recovered as a white solid. This
synthesis was repeated with longer reaction time (8 hours) and additional
Superhydride equivalents, as well as warming to ambient temperature. Neither
modification resulted in successful synthesis of this derivative.

Scheme 12. Attempted reduction of compound 3, 1,3-disubstituted carbamoyl 2pyrazoline to compound 4, 1,3-disubstituted carbamoyl pyrazolidine.

2.1.3: Modification of Ring C:20
All derivatives probing the influence of ring C upon ADH inhibition were
synthesized as described (Table 2). Ketone (83 mmol, 1.0 equiv.), dimethylamine
hydrochloride (108 mmol, 1.30 equiv.), and paraformaldehyde (108 mmol, 1.3
equiv.), and four drops of 0.4M hydrochloric acid was refluxed in a stirred
solution of 13.5 mL ethanol. This solution was cooled after 1.5 hours and 100 mL
of acetone was added. The resulting solid was washed and vacuum dried. A warm
solution of 26.4 mL methanol and this product was added over 10 minutes to a
solution of 5 mL hydrazine hydrate and 2.70 mL 50% sodium hydroxide in 6.70
mL methanol. This solution was refluxed for 45 minutes after which the methanol
was evaporated under reduced pressure to yield the 3-aryl substituted 2-pyrazoline
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product 5 as an oil. This product (5, 12.0 mmol, 1.00 equiv.) was dissolved in
40.0 mL dry ether with three drops of triethylamine and isocyanate (12.0 mmol,
1.00 equiv.). This solution was stirred for three days at room temperature and the
resulting solid was filtered and vacuum dried.

Table 2. Synthesis of derivatives with modification at the ring C position.

Compound #

R

Z

Yield

18
19

n-propyl
n-propyl

O
S

39.2%
6.90%

20
21
22

4-methoxyphenyl
4-chlorophenyl
4-nitrophenyl

O
O
O

80.0%
94.0%
83.2%

2.1.4: Modification of the Carbamoyl Region:21,34,35
The N- substituted 2-pyrazoline was prepared as described in the modification of
ring A and C (Scheme 13). 3-aryl substituted 2-pyrazoline (5, 12.5 mmol, 1
equiv.) was dissolved in 50 mL chloroform and cooled to 0°C. Triethylamine
(12.5 mmol, 1 equiv.) was added gradually to the solution. Butyric anhydride
(12.5 mmol, 1 equiv.) was added and the solution was stirred for three hours
while warming to room temperature. Solid precipitate resulted, which was
isolated via vacuum filtration and dried.
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Scheme 13. Synthesis of amide derivative 6 for investigation of the carbamoyl
region of N-substituted 2-pyrazolines.
Alkylation of a carbamoyl derivative was also investigated (Scheme 14)21. 3-(4chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole-carboxamide 8 (20.0 mg, 0.075
mmol, 1.00 equiv.), prepared previously was dissolved in 0.40 mL anhydrous
THF, under nitrogen. Sodium hydride (60.0%) (0.23 mmol, 3.00 equiv.) was
added to the solution and stirred one hour on ice. Methyl iodide (0.08 mmol, 1.00
equiv.) was added to the stirring solution dropwise and stirred. The reaction was
monitored by TLC with a 50% ethyl acetate: hexanes mobile phase. After two
hours the solution was cooled on ice and an additional equivalent of NaH was
added followed by an additional 1.50 equivalents of methyl iodide. After another
four hours an additional equivalent of methyl iodide was added. After another 24
hours stirring at room temperature under nitrogen, ice was added to the solution
and the resulting precipitate was filtered. The resulting crude yellow oil and solid
white precipitate was purified via gradient silica flash column chromatography
(12-52% ethyl acetate: hexanes) to isolate 6.3 mg of an off-white solid 9, in 29%
yield. (Recovered pyrazoline reactant, 15.6 mg).

Scheme 14. Synthesis of an alkylated N-propyl carbamoyl 2-pyrazoline
derivative.

20

Synthesis of the N- alkylated thiocarbamoyl derivative was also performed
(Scheme 15)35. 3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazolecarbothiamide 10 (25.0 mg, 0.089 mmol, 1.00 equiv.) was dissolved in 1 mL
DCM. This solution was chilled on ice before the gradual addition of methyl
iodide (0.14 mL, 2.3 mmol, 25 equiv.). This stirring solution was warmed to room
temperature and stirred at ambient temperature for 68 hours. The reaction was
monitored by TLC with a 4:1 hexanes: ethyl acetate mobile phase. This solution
was concentrated under reduced pressure, reconstituted in DCM, and washed with
10% NaOH. The organic layer was dried over MgSO4, filtered, and concentrated
to yield a crude yellow viscous oil (21.6 mg, 81% yield). This oil was purified
via silica flash column chromatography (4:1 hexanes: ethyl acetate) to yield 11 as
a white solid (8.8 mg, 33% yield).

Scheme 15. Synthesis of an alkylated N-propyl thiocarbamoyl 2-pyrazoline
derivative 11.

2.2: Enzyme Assays
Horse liver alcohol dehydrogenase sourced from Sigma Aldrich (A9589) was used for all
enzymatic kinetics assays. High-throughput enzyme kinetics screens were performed
with 0.25 mM NADH (cofactor), 0.25 M horse liver ADH, and 3 mM benzaldehyde
(substrate) in 50 mM triethanolamine (TEA) buffer pH 7.2. High-throughput enzyme
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kinetics assays were performed using a Spectro STAR Omega plate reader at 340 nm
with UV-Transparent polystyrene 96 well plates. The plate reader was set in plate mode
with a positioning delay of 0.2 seconds, a kinetic window of 1, 10 cycles, with 10 flashes
per well and cycle, and a cycle time of 15 seconds. The orbital shaking frequency was set
at 500 rpm with five seconds shaking before each cycle. The temperature of the plate
reader was maintained at 30 °C for all readings. Each kinetics assay trial was monitored
for a 5-minute time interval and temperature was maintained at 30 °C. A maximum of six
wells were used per trial assay to minimize error associated with mixing time. A positive
control and DMSO control were included for each assay trial to compare consistency
between individual runs. Prepared NADH and ADH stock solutions were stored at 4 °C
for long term storage (two months NADH, two weeks ADH).

Several method conditions were employed for enzyme assay optimization, positive
inhibition controls, and inhibitor trials. All assay conditions monitored the decrease in
absorbance at 340 nm resulting from the conversion of NADH (absorbs at 340 nm) and
NAD+ (minimal absorbance at 340 nm) cofactors accompanying the conversion of
benzaldehyde substrate to benzyl alcohol (Scheme 16). All enzyme activity slopes
reported are measured in units of M sec-1.
NAD+

NADH

O

OH

H
Monitoring 340nm

Scheme 16. Conversion of benzaldehyde to benzyl alcohol performed by ADH and
monitored in enzyme assays with decrease in absorbance at 340 nm.
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2.2.1: Method A
This method was employed for high throughput enzyme screens with substrate
added last and readings using an incubated plate reader. Plates were prepared with
NADH, ADH, DMSO or diluted samples (1, 10, and 100 M final inhibitor
concentration), and buffer at room temperature and incubated five minutes in the
plate reader at 30 °C, with shaking every 10 seconds at 500 rpm. After incubation,
benzaldehyde was added, mixed by pipetting, and immediately inserted for kinetic
readings at 340 nm. The average time between benzaldehyde addition and the
initial reading was approximately 15 seconds.

2.2.2: Method B
This method was employed for high throughput enzyme screens with cofactor
added last and readings using an incubated plate reader. Plates were prepared with
NADH, benzaldehyde, DMSO or diluted samples (1, 10, and 100 M final
concentration), and buffer at room temperature and incubated 5 minutes in the
plate reader at 30 °C, with shaking every 10 seconds at 500 rpm. After incubation,
ADH was added, mixed by pipetting, and immediately inserted for kinetic
readings at 340 nm. The average time between ADH addition and the initial
reading was approximately 15 seconds.

2.2.3: Method C
This method was employed for assay verification using a double beam UV-Vis
spectrophotometer and quartz cuvettes. Following Method A described above
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except performed using a Cary 5000 spectrophotometer with 1 cm quartz
cuvettes. The same concentration of reagents was used, with benzaldehyde added
post incubation at 30 °C. This instrument does not feature temperature control, so
cuvettes were incubated in a water bath at 30 °C and ambient temperature was
approximately 27 °C.

2.2.4: Method D
This method was employed to identify interference at the monitoring wavelength
for assay components. Several assays were also performed using a Cary 5000
UV-Vis-NIR spectrophotometer with 1 cm quartz cells. These assays verified that
the enzyme initial rate was appropriately monitored under these assay conditions.
For several trials, the same concentration of reagents was used from Method A
and the volume was adjusted to a cuvette final volume of 600 L. Additional
trials including double substrate (i.e. 6 mM benzaldehyde) or double co-factor
(i.e. 0.5 mM NADH) concentration were included.

2.2.5: Method E
This method was employed to identify interfering absorbencies near the
monitoring wavelength for assay components. Wavelength scans from 280- 400
nm were also done to determine if interactions between assay components
influenced absorbance readings. These assays used the same reagent
concentrations as Method A but some assay components were omitted in each
trial. The final cuvette volume was adjusted to 600 L for all combinations. All
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trials were performed with 3 L DMSO added and measurements were taken
immediately after reagent addition using the Cary 5000 instrument at ambient
temperature.

2.2.6: Method F
This method was employed to monitor the change in absorbance of tested
inhibitor derivatives at different buffer pH conditions to assess any compound
degradation at the pH employed. Trials were performed with 100 M of
compound 6 in TEA buffer ranging from pH 4.19 to 8.90. Buffer pH was adjusted
using a Fisherbrand Accumet AB150 pH meter and the addition of 1 N
sodium hydroxide or 1 N hydrochloric acid. Wavelength scans were recorded for
only buffer and compound 6 from 280 to 400 nm over five minutes to monitor the
stability of assay components at varied buffer pH. These measurements were
recorded at room temperature using the Cary 5000 instrument and 1 cm quartz
cuvettes.

A minimum of three trials were performed for each compound or control. Reported
slopes represent the average of all slopes from all trials at a given concentration.
Reported remaining activity was calculated using the ratio of the average slope for each
concentration over the average of all DMSO control runs. The average and standard
deviation was calculated for each compound and percent remaining activity was
calculated as the ratio between the average slope of each compound trial and the average
of all DMSO standard runs. Outliers were determined and eliminated if they fell outside
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of the lower 25% and upper 75% bounds of the data set determined by the first and third
quartile calculations. Outliers were determined as those that lie outside of 1.5 times the
inner quartile range.

2.3: Ternary Complex Fluorescence Analysis
Fluorescence spectroscopy analysis was performed on combinations of assay components
to monitor ternary complexation between ADH and NADH with DMSO as a co-solvent.
Previous studies identified a ternary complex for NADH bound to ADH with
fluorescence emission at approximately 420 nm for an excitation wavelength of 328 nm
at pH 7.236. The following combinations of assay components were analyzed for their
fluorescence emission intensity at the concentrations used in Method A: (1) NADH,
ADH, ADH and DMSO scanned immediately upon addition, (2) NADH and ADH
scanned immediately upon addition, (3) NADH and ADH incubated for five minutes at
30 °C, and (4) ADH, NADH, and DMSO incubated for five minutes at 30 °C. 1 cm
quartz fluorescence spectroscopy cells were used for all measurements. A Horiba
Fluorolog 3 spectrofluorometer with FluorEssence 3.0.0 software was used for all
fluorescence measurements. The excitation wavelength used for all scans was 328 nm
with a slit width of 1 nm and an increment of 1 nm for a monitoring frame of 338- 550
nm.

2.4: AutoDock Docking Analysis
ChemDraw 15.0 Professional MM2 Minimization calculations were used to determine
the lowest energy conformation of pyrazoline 1 based upon computation of the
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conformation with the fewest steric interactions based upon free rotation about sigma
bonds. The default parameters were used for MM2 minimization in ChemDraw3D with a
step interval of 2 fs, frame interval of 10 fs and 10,000 iterations. AutoDock Version
1.5.6 with AutoDock tools and an X-Quartz X11 display server was used for all analyses.
Standard AutoGrid ligand docking analysis was performed with the system default
parameters.
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Chapter 3: Results
3.1: AutoDock Docking Analysis
ChemDraw Professional 15.0 MM2 Minimization was used to generate the lowest energy
conformer for pyrazoline 1 which was used for docking analysis (Figure 6).

Figure 6. Three-dimensional representation (right) of the lowest energy conformation of
compound 1 (left) in AutoDock as determined by ChemDraw Professional 15.0 MM
Minimization calculation.

Autodock software was used to visualize a possible binding site for pyrazoline 1 if it was
to behave as a competitive inhibitor (Figure 7)33. Figure 7 illustrates a theoretical mode of
binding for pyrazoline 1 with the horse liver ADH active site (PDB 1HLD, Protein Data
Bank ID 4XD2, cofactor and substrate bound, assumed competitive inhibition) based
upon the minimized steric interactions. This theoretical model was generated with the
lowest energy conformation of 1 assuming the maximum number of rotational modes.
Figure 7 provides a topological representation of this binding interaction and is indicative
of a likely shallow binding interaction. A potential binding region for compound 1 is the
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active site for the alcohol dehydrogenase, which is a highly electrophilic region with
many hydrogen-bonding residues. The bent conformation of pyrazoline 1 overall may
orient the thiocarbamate group to face into the active site of the horse liver ADH with
phenyl groups facing outwards (Figure 7). These model approximations indicate a
shallow potential binding site that is available to water, which increases the number of
possible inhibitor conformations.

Figure 7. AutoDock modeling of the interaction between compound 1 and horse liver
ADH protein secondary structure, top/side view (left), top view (middle), and topological
representation (right).

The AutoDock viewing of the protein secondary structure identified a nonpolar active site
with several hydrogen bonding residues that may interact with inhibitors (Figure 7).
Residues at the substrate binding site include several polar residues (Serine-54 and
Threonine-56,59), many nonpolar residues (Valine-52,53,58,63, Glycine-55,66, Leucine57,61, Proline-60,62, Isoleucine-64, Alanine-65), and several positively charged residues
(Aspartic acid-49,50 and Histidine-51,67)31.
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3.2: Initial Enzyme Assay Optimization
Several modified assays were performed to verify that the assay was effective at
monitoring enzyme activity within the initial rate window. In the absence of enzyme,
benzaldehyde or NADH, a significant decrease in activity was observed (Table 3). Only
3.24±1.35 percent remaining activity was observed when NADH was removed relative to
the positive control containing all assay components. A greater change in absorbance
readings (at 340 nm) was observed in the absence of enzyme or benzaldehyde (Table 3).
This high change in absorbance in the absence of substrate or enzyme suggests autoreduction of the cofactor under the assay conditions. All enzyme activity slopes reported
are measured in units of M sec-1.

Table 3. Enzyme activity control assays. All assays performed according to Method C.
Slope

St. Dev.

RSD

Average Remaining Activity ±STD

Positive Control

-3.85E-04

4.44E-05

-0.12

100±0.00 (n=9)

No ADH
No
Benzaldehyde
No NADH

-1.40E-04

2.01E-04

-1.44

36.3±5.22 (n=3)

-1.73E-04

4.24E-05

-0.24

45.0±1.10 (n=3)

-1.25E-05

5.20E-05

-4.16

3.24±1.35 (n=8)

The role of enzyme concentration was investigated, and 60.8% activity was observed
with half enzyme concentration relative to the positive control (Table 4). This assay was
performed to verify that enzyme concentration was rate limiting with substrate and
cofactor in excess. This ensures that the assay exists under steady state conditions with
the concentrations of substrate and cofactor changing negligibly. This drives the
equilibrium to position in the desired direction, ensuring that the enzyme initial rate is
being monitored. An increase in activity was observed with double the enzyme
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concentration relative to the positive control (Table 4). The role of substrate
concentration was also investigated and a minimal increase in activity was observed
when the concentration of benzaldehyde was doubled (Table 5).
Table 4. Enzyme concentration assays. Assay performed according to Method C, with
indicated modification.

Enzyme

Slope

Percent Activity Relative to Positive
Control

Positive Control (0.25 M ADH)

-8.23E-04

100% (n=1)

Half ADH (0.13 M)

-5.01E-04

60.8% (n=1)

Double ADH (0.5 M)

-1.01E-03

122% (n=1)

Table 5. Substrate concentration assays. Assay performed according to Method C with
indicated modification.

Substrate

Slope

Percent Activity Relative to Positive
Control

3 mM Benzaldehyde

-6.91E-04

100% (n=1)

6 mM Benzaldehyde

-8.32E-04

120% (n=1)

3.3: Solvent Controls
All derivatives were screened with DMSO as a co-solvent. DMSO is a known
competitive ADH inhibitor with a Ki of 5 mM for horse liver ADH36. DMSO is the
standard solvent for high throughput screens and has been used up to 3% in screens of
acetaldehyde dehydrogenase activity37. Other suggested solvents included DMF which
also exhibits ADH inhibition and ethanol which is a substrate for the reverse reaction and
would influence kinetics readings38. Assays were performed to determine the optimal
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DMSO concentration for screening. The ideal volume of DMSO resulted in a maximum
remaining enzyme activity and minimal dispensing error. The greatest volume of DMSO
having the minimal impact upon ADH enzymatic activity was 3 L with 34.6%
remaining activity relative to the positive control without DMSO (Figure 8). This volume
of DMSO was used for all DMSO standard controls and derivative screenings. Stock
solutions were adjusted to maintain the same volume of DMSO in all assay trials for
reduced error associated with dispensing/ mixing. Significant inhibition was observed
upon the addition of DMSO likely resulting from inhibition of the enzyme by the solvent
as DMSO is a known ADH inhibitor36. Smaller volumes of DMSO exhibited similar
activity and were associated with pipet delivery error.

Percent Remaining Activity

120
100
80
60
40
20
0
0

1

2

3

4

5

DMSO ( L)
Positive Control

1 L DMSO

2 L DMSO

3 L DMSO

4 L DMSO

Figure 8. Percent remaining ADH activity with DMSO added to enzyme assay
conditions (Method C).
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3.4: Reagent Stability Assays
The change in absorbance over time was measured for various combinations of assay
components to ensure that non-enzyme interactions are not contributing to measured
activity monitored at 340 nm (Figure 9). An increase in absorbance was observed for
enzyme and NADH over time in the absence of substrate. A decrease in absorbance was
recorded for all other combinations including the positive control, which exhibited a large
drop in absorbance within 70 seconds (Figure 9). This suggests that the positive control
had the greatest decrease in absorbance at this wavelength. Other assay components do
influence measurements at this wavelength and these influences ought to be considered in

Absorbance at 340 nm

the calculation of enzyme activity within the screen assays.
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
-0.01
-0.02

NADH
NADH, and Benzaldehyde
100 M Compound 12
NADH and 100 M Compound 12
NADH, 100 M Compound 12,
and Benzaldehyde

0

100

200

300

Time (Seconds)
Figure 9. Enzymatic assays monitoring the change in absorbance over time at 340 nm for
varied combinations of assay components including ADH (Horse liver) and DMSO.
Compound 12 at 100 M, in pH 7.21 TEA buffer was assessed (with 3 L DMSO for
combinations without 100 M compound 12). Assays performed according to Method C
with the indicated modifications.
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The stability of these compounds at pH 7.21 (assayed pH) was of concern due to the lack
of dose dependence observed (1, 10, 100 M). One of the derivatives (compound 12, N3-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide), was examined at 100 M in
TEA buffer. The pH was varied from 4.19 to 8.90 while monitoring any change in
absorbance at 340 nm (Figure 10). This compound was selected and screened at this
concentration as an example of the 1,3-disubstituted 2-pyrazoline carboxamide
derivatives. Further studies would be required to determine the effects of pH upon other
derivatives. The slopes of the line of best fit for each of these conditions did not vary
greatly but the slope of the highest magnitude was observed at pH 5.71 (Table 6). This
suggests that there is not a significant decomposition of this or other screened
compounds. As some absorbance was observed across all pHs, this compound specific

Absorbance at 340 nm

absorbance must be accounted for in the background readings of the assay.
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
-0.005
-0.01
0

100

200

300

pH 4.19
pH 5.71
pH 7.21
pH 8.9

Time (Seconds)
Figure 10. Change in absorbance at 340 nm for 100 M compound 12 in TEA buffer
adjusted to pH ranging from 4.19 to 8.90. Assays were prepared according to Method C
with buffer pH adjusted as indicated.
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Table 6. Slope of the best fit line for the change in absorbance at 340 nm over time of
100 M compound 12 in TEA buffer, adjusted pH to range from 4.19 to 8.90.
TEA Buffer pH

Slope

4.19

-2.87E-05

5.71

-3.60E-05

7.21

-2.61E-05

8.90

-2.43E-05

Average
St. Dev.

-2.88E-05
5.15E-06

3.5: Positive Inhibition Control
4-Methylpyrazole was employed as the positive inhibition control compound for this
assay. DMSO was used as a solvent for 4-methylpyrazole and percent inhibition values
were calculated relative to the average of all DMSO standard trials. Dose dependent
inhibition of horse liver ADH activity was observed for Method A and B (Table 7 and
Table 8). The sequence of addition order within this screen assay does appear to matter at
the inhibitor concentrations employed in this study.

Table 7. Average screen inhibition assay trials for 4-methylpyrazole. Assays performed
according to Method A.

NH

N

Slope

St. Dev.

RSD

Average Remaining Activity
±STD

1 M

-4.04E-05

8.21E-06

-0.20

66.1±21.2% (n=6)

10 M

-2.33E-05

2.55E-06

-0.11

39.8±6.73% (n=5)

100 M

-2.08E-05

7.71E-07

-0.04

36.4±1.14% (n=4)
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Table 8. Average screen inhibition assay trials for 4-methylpyrazole. Assays performed
according to Method B.

NH

N

Slope

St. Dev.

RSD

Average Remaining Activity
±STD

1 M

-7.84E-05

1.92E-05

-0.24

107±33.4% (n=7)

10 M

-5.46E-05

1.18E-05

-0.22

74.5±20.5% (n=6)

100 M

-4.88E-05

5.67E-06

-0.12

66.7±9.86% (n=6)

3.6: Inhibition Comparison
For all enzyme assays, “significant inhibition” activity was (arbitrarily) defined as 80100% inhibitory efficiency relative to the positive inhibition control, 4-methylpyrazole
with benzaldehyde added last (Table 7). “Moderate activity” was defined as 60-80%
inhibitory efficiency relative to 4-methylpyrazole. “Minimal activity” was defined as 060% inhibitory efficiency relative to 4-methylpyrazole. The importance of addition order
was investigated with either benzaldehyde (Method A) or enzyme added after incubation
(Method B) for 5 minutes. The most consistent results were identified with benzaldehyde
added after incubation. All compounds were screened with benzaldehyde added last but
the data for several compounds with enzyme added last are also included for comparison.

3.6.1: Modification of the carbamoyl region
The 1,3-diaryl pyrazoline base structure (compound 3, N,3-diphenyl-4,5-dihydro-1Hpyrazole-1-carboxamide) exhibited the highest ADH inhibition at 10 M (Method A,
Table 9). No significant inhibition was observed for this compound with enzyme added
after incubation and minimal increase in enzyme activity was observed relative to the
average of all DMSO controls. Modification of the carbamoyl of the base structure to a
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thiocarbamoyl functional group (compound 12) resulted in no significant enzyme
inhibition at any of the screened concentrations. Modification of the carbamoyl region of
the pyrazoline base structure to an amide functional group (compound 6) resulted in no
significant ADH inhibition for neither Method A nor B (Table 9 and Table 10). No
significant inhibition was observed in response to changes in addition order for
compound 3 or 6. Alkylation of the nitrogen of the carbamoyl region for a 3-pchlorophenyl-N-propyl-carbamoyl 2-pyrazoline derivative (compound 9) resulted in poor
ADH inhibition for all concentrations screened and no dose dependent inhibition was
measured. Alkylation of the sulfur of a 3-p-chlorophenyl-N-propyl-thiocarbamoyl 2pyrazoline derivative (compound 11) resulted in significant inhibition at all
concentrations screened and dose dependent inhibition was measured.
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Table 9. Average screen inhibition assay trials for compounds (3, 6, 9, 11, and 12)
synthesized to probe role of carbamoyl moiety for ADH inhibition by 1,3-disubstituted
carbamoyl 2-pyrazolines. Assays performed according to Method A.
Slope

St. Dev.

RSD

Average Remaining
Activity ±STD

1 M

-6.86E-05

1.55E-05

-0.23

119±29.6% (n=6)

10 M

-5.03E-05

1.31E-05

-0.26

85.6±31.6% (n=6)

100 M

-7.50E-05

1.78E-05

-0.24

131±25.1% (n=6)

1 M

-5.67E-05

5.79E-06

-0.10

98.6±10.1% (n=6)

10 M

-6.30E-05

2.69E-06

-0.04

110±4.68% (n=4)

100 M

-6.62E-05

9.65E-06

-0.15

115±16.8% (n=6)

1 M

-6.17E-05

1.76E-06

-0.28

107±30.7% (n=4)

10 M

-4.89E-05

7.79E-06

-0.16

85.1±13.6% (n=4)

100 M

-9.18E-05

3.14E-05

-0.34

159±54.6% (n=2)

1 M

-3.46E-05

2.96E-05

-0.85

60.2±51.5% (n=4)

10 M

-3.43E-05

9.27E-06

-0.27

59.7±16.1% (n=4)

100 M

-2.57E-05

1.05E-05

-0.47

44.8±18.2% (n=4)

1 M

-5.41E-05

6.87E-06

-0.13

83.0±17.1% (n=3)

10 M

-6.56E-05

2.07E-05

-0.32

108±36.0% (n=6)

100 M

-6.24E-05

3.36E-05

-0.54

330±18.5% (n=4)

Compound
3

6

9

11

12
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Table 10. Screen inhibition assay trials for compounds (3 and 6) synthesized to probe
role of the carbamoyl moiety for ADH inhibition by 1,3-disubstituted carbamoyl 2pyrazolines. Assays performed according to Method B.
Slope

St. Dev.

RSD

Average Remaining
Activity ±STD

1 M

-7.06E-05

4.76E-06

-0.07

96.4±8.29% (n=3)

10 M

-7.78E-05

7.89E-06

-0.10

106±13.7% (n=3)

100 M

-8.23E-05

1.11E-05

-0.14

112±19.4% (n=3)

1 M

-7.06E-05

4.76E-06

-0.07

102±29.0% (n=3)

10 M

-7.78E-05

7.89E-06

-0.10

97.4±17.5% (n=3)

100 M

-8.23E-05

1.11E-05

-0.14

111±29.3% (n=3)

Compound
3

6
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3.6.2: Modification of Ring A
The role of ring A in 1,3-disubstituted carbamoyl 2-pyrazoline inhibition activity was
investigated through enzyme inhibition screening assays (Table 11). The aryl ring was
modified to a methyl group and this derivative exhibited only minimal ADH inhibition at
10 M (compound 17). The electron donating p-methoxyphenyl group resulted in
moderate enzyme inhibition at 1 and 10 M concentrations (compound 14). A pmethylphenyl group resulted in moderate enzyme inhibition for all concentrations
screened (compound 15). The electron withdrawing p-chlorophenyl group resulted in
moderate enzyme inhibition at 1 and 10 M but regained activity at 100 M (compound
13). Additionally, p-fluorophenyl substituent resulted in significant enzyme inhibition for
all concentrations screened with the highest inhibition observed at 10 M (compound
16). The p-chlorophenyl thiocarbamoyl 2-pyrazoline derivative was also screened and
resulted in only minimal enzyme inhibition at 1 M (compound 1). None of these
derivatives exhibited dose dependent inhibition across all three screened concentrations.
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Table 11. Screen inhibition assay trials for compounds (1, 13- 17) synthesized to probe
role of ring A for ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazolines. Assays
performed according to Method A.
Slope

St. Dev.

RSD

Average Remaining
Activity ±STD

1 M

-5.01E-05

1.48E-05

-0.29

87.1±25.7% (n=3)

10 M

-6.36E-05

3.98E-05

-0.63

111±69.3% (n=4)

100 M

-7.94E-05

8.05E-06

-0.10

138±14.0% (n=4)

1 M

-3.59E-05

7.25E-06

-0.20

62.6±12.6% (n=4)

10 M

-4.46E-05

1.93E-05

-0.43

77.7±33.6% (n=4)

100 M

-6.88E-05

1.38E-06

-0.02

120±2.41% (n=3)

1 M

-4.33E-05

1.74E-05

-0.40

75.3±30.3% (n=3)

10 M

-3.27E-05

7.64E-06

-0.23

57.0±13.3% (n=4)

100 M

-5.95E-05

1.98E-05

-0.33

104±34.5% (n=4)

1 M

-3.82E-05

2.67E-05

-0.70

66.5±46.5% (n=4)

10 M

-4.38E-05

1.71E-05

-0.39

76.3±29.8% (n=4)

100 M

-4.16E-05

9.44E-06

-0.23

72.3±16.4% (n=3)

1 M

-3.95E-05

6.04E-06

-0.15

68.7±10.5% (n=3)

10 M

-2.58E-05

8.63E-05

-3.34

45.0±150% (n=4)

100 M

-3.46E-05

1.73E-05

-0.50

60.2±30.0% (n=4)

1 M

-7.41E-05

1.58E-05

-0.21

109±31.5% (n=6)

10 M

-4.81E-05

1.76E-05

-0.37

95.2±30.6% (n=6)

100 M

-6.28E-05

4.62E-06

-0.07

104±21.3% (n=6)

Compound
1

13

14

15

16

17
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3.6.3: Modification of ring C
The role of the ring C moiety was also investigated through screening assays (Table 12).
The N-propyl carbamoyl 2-pyrazoline derivative investigated exhibited no significant
ADH inhibition at the concentrations screened (compound 18). The N-propyl
thiocarbamoyl 2-pyrazoline derivative investigated also exhibited no significant ADH
inhibition at the concentrations screened (compound 19).

Substituents at the para position of the N-phenyl ring were introduced with substituents
of varying electron donating or withdrawing character. None of these derivatives
exhibited dose dependent inhibition over the screened concentrations. The electron
donating p-methoxyphenyl group resulted in moderate enzyme inhibition at 1 and 10 M
concentrations (compound 20). The strong electron withdrawing p-nitrophenyl group
resulted in minimal enzyme inhibition at 1 and 10 M concentrations but significant
inhibition at 100 M (compound 22). A p-chlorophenyl group resulted in moderate ADH
inhibition at all concentrations, with the highest enzyme inhibition observed at 1 M
(compound 21).

42

Table 12. Screen inhibition assay trials for compounds (18- 22) synthesized to probe
role of ring C for ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazolines. Assays
performed according to Method A.
Slope

St. Dev.

RSD

Average Remaining
Activity ±STD

1 M

-4.73E-05

2.61E-05

-0.55

82.4±45.5% (n=4)

10 M

-5.63E-05

9.95E-06

-0.18

98.0±17.3% (n=4)

100 M

-5.65E-05

6.20E-06

-0.11

98.4±10.8% (n=3)

1 M

-5.41E-05

6.87E-06

-0.13

94.1±12.0% (n=4)

10 M

-6.56E-05

2.07E-05

-0.32

114±36.0% (n=6)

100 M

-6.25E-05

3.36E-05

-0.54

109±58.5% (n=5)

1 M

-3.63E-05

1.84E-05

-0.51

63.1±32.1% (n=4)

10 M

-4.02E-05

9.82E-06

-0.24

70.0±17.1% (n=4)

100 M

-6.85E-05

5.58E-06

-0.08

119±9.7% (n=4)

1 M

-1.88E-05

2.24E-05

-1.19

32.7±38.9% (n=4)

10 M

-3.34E-05

1.21E-05

-0.36

58.2±21.0% (n=4)

100 M

-3.95E-05

1.61E-05

-0.41

68.8±28.0% (n=4)

1 M

-4.62E-05

1.16E-05

-0.25

80.5±20.2% (n=4)

10 M

-5.53E-05

7.67E-06

-0.14

96.3±13.3% (n=3)

100 M

-2.51E-05

3.99E-05

-1.59

89.0±69.4% (n=4)

Compound
18

19

20

21

22
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3.7: Ternary Complex Analysis
Florescence spectroscopy analysis was performed with various combinations of the assay
components to monitor ternary complexation between ADH and NADH in the presence
of DMSO. Previous studies identified increased fluorescence emission intensity at
approximately 420 nm with NADH binding to ADH39. An increase in emission intensity
at 455 nm was observed for all assay component combinations investigated, except for
ADH alone. ADH alone did not exhibit significant emission with this excitation
wavelength and a minor peak was observed at 370 nm (Figure 11). The incubated sample
of NADH and ADH exhibited lower fluorescence emission intensity at 455 nm relative to
the other samples analyzed (Figure 11).
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Figure 11. Fluorescence emission scans for assay components excited at 328 nm.
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Chapter 4: Discussion and Conclusions
4.1: Discussion
This study evaluated the inhibitory efficiency of 1,3-disubstituted carbamoyl 2-pyrazoline
derivatives as horse liver alcohol dehydrogenase inhibitors. The assay used in this study
was effective for high throughput screening of inhibitors, but further assay optimization
would allow for more accurate activity determination. The high throughput assay
performed allowed for rapid determination of inhibitory activity with a larger sample size
than standard 1 cm cuvette trials would allow. However, this method introduced
additional error with mixing and dispensing such small volumes. Further optimization of
the assay conditions is necessary to minimize error associated with solvent influences and
background change in absorbance at the monitoring wavelength for assay components.

Positive control trials including all assay components (ADH, NADH, benzaldehyde, and
buffer) were included with every screen to monitor experimental variation between trials.
Minimal variation was observed for all positive controls with an average change in
absorbance of -2.57E-04± 9.99E-05 (n=63) with a relative standard deviation of 0.38
using Method A. These assay conditions exhibited measurable change in absorbance
within the instrument detection limit and this method was deemed suitable for high
throughput screens. Several modifications of assay concentrations were used to verify
that kinetics readings fall within the initial rate for horse liver ADH (Table 3, Table 4,
Table 5). Double enzyme concentration resulted in 122% activity relative to the positive
control indicating that substrate was in excess at the concentration used for screening
(Table 4). However, since this value was not directly correlated with enzyme
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concentration, the concentrations used may be nearing the end of the enzyme kinetics
initial rate region.

This study offered an effective method for rapid screening of derivatives and approximate
inhibitory efficiency. Optimization of the enzyme kinetics assay in response to these
finding is necessary to decrease error associated with measurement and to validate
inhibition results. Kinetics assays monitoring the change in absorbance of assay
components over time at the wavelength of interest identified changes that may
contribute to error associated with measured inhibition values (Figure 9, Table 6). A
decrease in absorbance with enzyme and 100 M compound 12 suggested possible
metabolism of the compound as a substrate or cofactor analog (Figure 9).

The addition order of assay components also influenced absorbance values with
benzaldehyde added last exhibiting lower variation between runs. Adding enzyme last did
not allow for incubation of the enzyme with cofactor and addition of the smaller volume
(3 L) may have contributed to mixing and pipet dispensing error. The difference in
activity in response to addition order suggests that time required for co-factor binding is
important for accurately monitoring enzyme activity.

Dimethylsulfoxide, DMSO, was used as a co-solvent for screening. Other suggested
solvents include ethanol and methanol, but as these alcohol solvents closely resemble the
substrate for the reverse reaction, an alternative solvent was necessary. DMSO is the
standard solvent for high-throughput screenings in pharmaceutics and biotechnology but
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there are known effects of DMSO on alcohol dehydrogenase activity40. DMSO is a
known competitive inhibitor of ADH with a Ki of 0.005M.39 This solvent is known to
react with the enzyme and NADH complex to form a ternary complex with fluorescent
properties.39 A mixed solvent system may be investigated if solubility within these
inhibition assays continues to be a challenge. The small 3 L volume (2%) of DMSO was
selected for all assays because it exhibited the highest percent remaining activity relative
to the positive control and this volume was associated with our lowest pipet delivery error
(Figure 8).

Percent remaining activity for all derivative screens were compared to the DMSO
standard runs to account for enzyme inhibition by the co-solvent. The significant
inhibition of ADH activity by DMSO has been of concern due to error associated with
monitoring a small fraction of total enzyme activity and potential conformational changes
resulting from the co-solvent. Inhibition due to the DMSO co-solvent may result from
conformational changes with DMSO- coordination which would alter ligand docking and
these screens may not be representative of natural ADH activity/ inhibition. Ligand
coordination in the presence of DMSO may influence the binding of these compounds
and measured inhibition values41.

Solubility of the screened inhibitors may cause the observed absorbance interference at
higher screen concentrations. Several derivatives precipitated out of solution at higher
assay concentrations (250 M and 1 mM). Fine particulates not visible to the eye within
the 10 and 100 M assay wells may contribute to increased enzyme activity observed for
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several compounds. Alternative co-solvents should be investigated to address issues with
solubility and ADH inhibition.

4-Methylpyrazole was employed as the positive inhibitor control compound for this study
due to its demonstrated ADH inhibition2. ADH inhibition by this compound was used to
evaluate the efficiency of synthesized derivatives as horse liver ADH inhibitors. A linear
dose dependent response was not observed for 4-methylpyrazole trials which it
suggestive that additional assay optimization may be required for this assay to replicate
literature results (Table 7 and Table 8).

Figure 12. Horse liver ADH inhibitors identified through high throughput inhibition
screening assays of 1,3-disubstituted carbamoyl 2-pyrazoline derivatives.

The systematic modification of electronic and steric factors surrounding the carbamoyl 2pyrazoline scaffold identified several effective horse liver ADH inhibitors at the
concentrations screened. The synthesized 1,3-disubstituted carbamoyl 2-pyrazoline
derivatives that resulted in horse liver ADH inhibition are shown in Figure 12.
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This discussion of compound structural attributes will follow the observed ADH
inhibition potency of the screened compounds.

The compound with the greatest inhibition was compound 21, N-(4-chlorophenyl)-3phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide, with 32.7± 38.2% remaining activity at
1 M (Table 12). However, this ring C modification derivative was only moderately
effective at higher concentrations and did not exhibit a dose dependent response. The
success of this compound at a low concentration suggested that decreased electron
density with ring C may contribute to ADH inhibition. Strong electron withdrawing or
electron donating groups on ring C (compound 22 and 20, respectively) failed at ADH
inhibition which suggested that the net dipole of this region may not be an important
factor for ADH inhibition. Removal of ring C, as with 3-phenyl-N-propyl carbamoyl and
thiocarbamoyl 2-pyrazoline derivatives (compounds 18 and 19) resulted in minimal
inhibition at all concentrations screened (Table 12). This suggested that aromatic
character at ring C may be an important factor for ADH inhibition.

Derivatives investigating the role of the carbamoyl region of 1,3-disubstituted carbamoyl
2-pyrazolines within ADH inhibition (Table 9) only identified successful inhibition with
the alkylated thiocarbamoyl derivative (compound 11). This derivative exhibited 44.8±
18.2% remaining activity at 100 M. The ADH inhibition of this compound was
comparable to that of 4-methylpyrazole at 100 M (36.4± 1.14%, Table 7). The 3phenyl-2-pyrazoyl butanamide (compound 6), the N,3-diphenyl thiocarbamoyl 2pyrazoline (compound 11) and the N,3-diphenyl carbamoyl 2-pyrazoline (compound 9)
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derivatives did not exhibit any ADH inhibition at the concentrations screened (Table 9).
The ADH inhibition for these modifications suggested that non-polar interactions with
the active site may be involved with ADH inhibition and the acyclic nitrogen of the
carbamoyl group plays a minimal role within ADH inhibition.

Modifications of the electronic character of ring A also exhibited significant ADH
inhibition for several of the concentrations screened (Table 11). Many ring A
modification derivatives provided ~60% inhibition activities at the 1 M concentration
(compounds 13,15 and 16). The most effective derivative of ring A modification
derivatives at 1 M was identified as compound 13, 3-(4-chlorophenyl)-N-phenyl-4,5diphenyl-1H-pyrazole-1-carboxamide. This derivative exhibited 62.6± 12.6% remaining
activity at 1 M and 77.7± 33.6% at 10 M. Compound 16, 3‐(4‐fluorophenyl)‐N‐phenyl‐
4,5‐dihydro‐1H‐pyrazole-1-carboxamide, was also identified as an effective horse liver
ADH inhibitor with 45.0± 15.0% remaining activity at 10 M. The inhibitory activity of
compound 16 was similar to that of 4-methylpyrazole at this concentration (39.8±17.0%)
at 10 M (Table 7). The inhibition by ring A derivatives having electron withdrawing
substituents suggested the importance of electronic character of this ring for ADH
inhibition. However, an electron donating para- methoxyphenyl group (compound 14)
also exhibited ADH inhibition with 57.0± 13.3% remaining activity at 10 M (Table 18).
Thus, the lack of change in ADH inhibition with varied ring A modifications implied
that, other than having the aryl ring itself, its electronic properties may play a minor role
in ADH inhibition.
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Comparing the enzyme inhibition results from all of these structural modifications does
not highlight an essential role of any single structural position for horse liver ADH
inhibition. Thus, a combination of electronic and steric influences at these multiple
positions are likely to be responsible for ADH inhibition. Thus, there was not a single
pharmacophore with 1,3-disubstituted 2-pyrazolines and multiple factors influence their
ADH inhibitory activity.

The lack of dose dependence for all of these derivatives suggested errors with the assay,
compound degradation/ metabolism, solubility issues, or an atypical mode of inhibition.
The cause of the dose independent response was not identified for these derivatives.
These results highlight the need for experimental optimization of a high- throughput
inhibition screens for ADHs and the need to elucidate the operative mechanism of
inhibition/ action of 1,3- disubstituted carbamoyl 2-pyrazoline compounds.

The stability of compounds at the buffer pH used for screening assays was investigated
through absorbance changes over a wide pH range (4.19- 8.90) (Figure 10). Compound
12 exhibited the greatest absorbance at pH 5.71 at 340 nm and the lowest absorbance at
pH 8.90 at 340 nm. Degradation may then be occurring under these extreme pH
conditions. In order to confirm/ discredit metabolism or degradation of substituted 2pyrazoline derivatives at these pH conditions and under the assay conditions, NMR
and/or GC/MS analysis may be pursued.
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Limitations of this study included inhibition of ADH activity by DMSO, insolubility of
derivatives at higher concentrations, and ternary complex formation. Given the inhibition
of the target ADH enzyme by the co-solvent, only minimal enzyme activity was available
to monitor and inhibit. Solubility challenges with pyrazoline compounds at higher
concentrations also may introduce errors associated with absorbance measurements.
Ternary complex formation was required for activity with the coordination of NADH cofactor with ADH; ternary complex formation was anticipated between NADH and ADH
as monitored by an increase in absorbance at 420 nm. Minimal ternary complex
formation was detected under the assay conditions that included the DMSO, indicating
that co-factor binding, or lack thereof, may be contributing to error associated with screen
assays (Figure 11).

4.2: Conclusion
This study was aimed at identifying effective ADH inhibitors for their potential
application as anti-parasitic and anti-bacterial agents. A series of 1,3-disubstituted
carbamoyl 2-pyrazoline derivatives were synthesized with variable steric and electronic
properties to investigate and identify the pharmacophore required for ADH inhibition.
Several compounds synthesized and screened in this study exhibited moderate horse liver
ADH inhibition, with few compounds exhibiting inhibition similar to 4-methylpyrazole.
This study suggests that some 1,3-disubstituted 2-pyrazolines are effective horse liver
ADH inhibitors but the mode of inhibition (competitive/ uncompetitive/ noncompetitive/
mixed) of these compounds remains to be determined.
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Electronic and steric interactions at the carbamoyl position were anticipated to play a
major role in enzyme inhibition given the performed computational modeling studies.
Alkylation of the sulfur of the 3-chlorophenyl-N-propyl thiocarbamoyl derivative resulted
in significant inhibition. Activity observed with the alkylated thiocarbamoyl derivative
suggested that the exocyclic nitrogen (of the thiocarbamoyl group) does not play an
essential role in ADH inhibition and nonpolar interactions may increase ADH inhibition.
Derivatives with substituents at the para position on rings A and C were shown to effect
ADH inhibition. This study illustrated that para electron donating groups on ring A
increased ADH inhibition. Thus, the electronics of ring A (and greater electron density
contributing to the pyrazoline ring) contribute to ADH inhibition. Additionally, decreased
electron density at ring C was associated with increased ADH inhibition. Overall, there
was not a single pharmacophore identified through our described studies and multiple
factors influence ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazoline
compounds. The assay used to screen inhibitors must be further optimized to verify the
activity of these compounds and to eliminate extraneous variables, including solubility,
decomposition, or substrate analog metabolism.
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Chapter 5: Future Studies
5.1: Assay Optimization
Additional studies are required to optimize the inhibition screen assay employed within
this study. Additional trials of each inhibitor and standards would minimize error
associated with measurement and improve accuracy. The source of positive inhibition
values should be investigated to determine the mechanism of action behind any enzyme
activity enhancement. The error associated with DMSO inhibition should be investigated
and, in the event, that this error cannot be minimized another co-solvent or colorimetric
assay should be attempted42. An alternative solvent system may also increase compound
water solubility and decrease the observed error associated with DMSO as the co-solvent,
avoiding ADH inhibition. A colorimetric assay could also be employed. One such as that
monitoring the reduction of nitroblue tetrazolium (NBT) with the reduction of NADH in
the presence of phenazine methosulphate (PMS) with the change in absorbance at 590 nm
may offer an alternative to monitoring directly the cofactor conversion at 340 nm42. This
method would also allow for high throughput screening of derivatives avoiding
background absorbances of assay components.

Several studies were performed investigating the role of addition order on enzyme
activity and inhibition. Additional trials would help to minimize error and identify the
optimal addition order. pH dependent effects were investigated for one compound, but
studies of additional compounds would help to establish a relationship between pH and
compound stability. Structure identification of the compounds at different pH values
would help to determine if the derivatives are metabolized or decomposed at the assay
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pH. Further assays and studies would be needed to determine if these pyrazoline
derivatives behave as substrate or co-factor analogs for ADH.

5.2: Mode of Action
The mode of inhibition for these compounds remains unknown and classic Lineweaver
Burke kinetics analysis should be used to determine the mode of inhibition for successful
compounds. At this time, solubility of the compounds at high concentrations preclude
such measurements. The determination of Ki and IC50 values would improve comparisons
of compound efficiency and determine the mode of inhibition.

5.3: AutoDock Modeling
AutoDock modeling may be used for successful inhibitors to understand potential
competitive binding interactions between the enzyme and the derivatives. Modeling with
the crystal structure of horse liver ADH with substrate, cofactor, and DMSO bound
(assuming competitive inhibition) would increase the accuracy of these approximations.
The crystal structure of successful inhibitors may also allow for more appropriate
AutoDock modeling analysis. AutoDock analysis with the crystal structure of human or
bacterial ADH would also allow for an approximation of the binding modes of these
compounds for different targets and applications.

5.4: Additional Derivatives
Future studies should also include the screening of additional derivatives. Several other
compounds are of interest have yet to be synthesized that probe the pyrazole core and
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sterics surrounding the carbamoyl position (Figure 13). A pyrazolidine derivative would
probe the role of aromaticity and electron density at ring B in ADH inhibition. This
reduction was attempted several times with Superhydride as a reducing agent with no
conversion. Alternative reduction conditions will be investigated to achieve this
transformation.

Figure 13. Several proposed derivatives probing the pyrazole core and sterics
surrounding the carbamoyl position.

Additionally, oxidation of the pyrazoline ring to a pyrazole would probe the role of
increased electron density at ring B in ADH inhibition. Investigation of N-phenyl and Npropyl pyrazole derivatives would investigate the influences of aromaticity and steric
interactions at ring C. This oxidation has been achieved for three pyrazole derivatives
(compounds 2, 23, and 24) but time did not permit for adequate purification and high
throughput screening to determine inhibitory activity of these derivatives.

Furthermore, a 1,3-diphenyl 2-pyrazolylcarbamide derivative (26) was synthesized to
target the role of the exocyclic nitrogen of the carbamoyl region. Additionally, a
derivative completely lacking the carbamoyl moiety (25) would investigate the
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importance of the carbamyl dipole. Both of the latter derivatives were synthesized but
time did not permit for adequate purification and high throughput screening to determine
their ADH inhibition. Investigation of this series of derivatives would identify the role of
the pyrazoline and carbamoyl regions in ADH inhibition.
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Supplemental Information A
Compound 5

Synthesis of 3-phenyl-4,5-dihydro-1H-pyrazole:
Acetophenone, (9.90 mL, 83.2 mmol, 1.00 equiv.), dimethylamine hydrochloride (8.89 g,
108 mmol, 1.30 equiv.), and paraformaldehyde (3.30 g, 108 mmol, 1.30 equiv.) and four
drops of 0.40 M hydrochloric acid was refluxed in a stirred solution of 13.5 mL of ethanol.
After two hours, the solution was cooled and 100 mL of acetone was added. The white
crystalline solid was washed and dried. A warm solution of 26.4 mL methanol and 37.0
mmol of this product was added to a solution of 5.00 mL hydrazine hydrate, and 2.70 mL
50% sodium hydroxide in 6.70 mL methanol over 10 minutes and refluxed for 45 minutes.
The methanol was evaporated under reduced pressure to yield 3-phenyl-4,5-dihydro-1Hpyrazole as an oil, in 50.7% yield.

Compound 7

Synthesis of 3-(4-chlorophenyl)-4,5-1H-pyrazole:
4-chloroacetophenone (2.50 g, 32.5 mmol, 1 equiv.), dimethylamine hydrochloride (2.62
g, 32.1 mmol, 1 equiv.), paraformaldehyde (1.27 g, 42.4 mmol, 1.30 equiv.) and four drops
of 0.40 M hydrochloric acid was refluxed in a stirring solution of 5.20 mL ethanol. After
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two hours, the solution was cooled and 26.0 mL of acetone was added. The white
crystalline solid was washed and dried. A warm solution of 11.0 mL methanol and 22.2
mmol of this product was added to a solution of 2.25 mL hydrazine hydrate, and 1.11 mL
50% sodium hydroxide in 2.70 mL methanol over 10 minutes and refluxed for 45 minutes.
The methanol was evaporated under reduced pressure to yield 3-(4-chlorophenyl)-4,5dihydro-1H-pyrazole as a white solid, in 47.5% yield.

Compound 27

Synthesis of 3-(4-methoxyphenyl)-4,5-1H-pyrazole:
4-chloroacetophenone (2.03 g, 13.3 mmol, 1.00 equiv.), dimethylamine hydrochloride
(1.51 g, 17.3 mmol, 1.30 equiv.), paraformaldehyde (0.56 g, 17.3 mmol, 1.30 equiv.), and
four drops of 0.40 M hydrochloric acid was refluxed in a stirring solution of 2.25 mL
ethanol. After two hours, the solution was cooled and 10.0 mL of acetone was added. The
white crystalline solid was washed and dried. A warm solution of 6.00 mL methanol and
this dried product (1.37 g, 7.80 mmol, 1 equiv.) was added to a solution of 1.50 mL
hydrazine hydrate, and 1 mL 50% sodium hydroxide in 2.00 mL methanol over 10 minutes
and refluxed for 45 minutes. The methanol was evaporated under reduced pressure to yield
3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole as a white solid, in 58.7% yield.
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Compound 28

Synthesis of 3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole:
4-methylacetophenone (2.09 g, 14.9 mmol, 1.00 equiv.), dimethylamine hydrochloride
(1.64 g, 19.4 mmol, 1.3 equiv.), paraformaldehyde (0.62 g, 19.4 mmol, 1.30 equiv.), and
four drops of 0.40 M hydrochloric acid was refluxed as a stirring solution of 2.50 mL
ethanol. After 1.5 hours, the solution was cooled and 10.0 mL of acetone was added. The
white crystalline solid was washed and dried. A warm solution of 4.00 mL methanol and
this dried product (0.92 g, 5.77 mmol, 1 equiv.) was added to a solution of 0.78 mL
hydrazine hydrate and 0.40 mL 50% sodium hydroxide in 1.00 mL methanol over 10
minutes and refluxed for 45 minutes. The methanol was evaporated under reduced pressure
to yield 3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole as a yellow solid, in 18.5% yield.

Compound 29

Synthesis of 3-methyl-4,5-dihydro-1H-pyrazole:
Methyl vinyl ketone (10.0 mL 176 mmol, , 1.00 equiv.) was added gradually to an ice-cold
solution of hydrazine hydrate (10.0 mL, 176 mmol, 1.0 equiv.) in 10.0 mL of methanol.
Upon addition, significant heat was generated, and the solution was maintained at 50°C for
two hours. The methanol was evaporated under reduced pressure to yield white solid
residue that was directed to the synthesis of compound 17 immediately.
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Compound 30

Synthesis of 3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole:
4-fluoroacetophenone (2.85 g, 20.6 mmol, 1.00 equiv.), dimethylamine hydrochloride
(2.26 g, 26.8 mmol, 1.33 equiv.), paraformaldehyde (0.80 g, 26.8 mmol, 1.33 equiv.) and
four drops 0.40 M hydrochloric acid was added to a stirring solution of 3.5 mL ethanol.
This solution was cooled after 1.5 hours and 10.0 mL acetone was added. White crystalline
solid was washed and dried. A warm solution of 10.0 mL methanol and this product (3.07
g, 18.7 mmol, 1.00 equiv.) was added to a solution of 2.00 mL hydrazine hydrate and 1.00
mL 50% sodium hydroxide in 3.00 mL methanol over 10 minutes and refluxed for 45
minutes. The methanol was evaporated under reduced pressure to yield 3-(4-fluorophenyl)4,5-dihydro-1H-pyrazole as a white solid residue, in 42.8% yield.
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Screened Inhibitor Compounds
Compound 1

Synthesis of 3-(4-chlorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide:
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (1.91 g, 10.5 mmol, 1.00 equiv.) was
dissolved in 55.0 mL anhydrous ether with two drops of triethylamine and phenyl
isocyanate (2.51 mL, 18.5 mmol, 1.00 equiv.) phenyl isothiocyanate. This solution stirred
1.5 hours at room temperature and the solid yellow product was filtered and dried, in 39.4%
yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 9.05 (bs,1H) 7.66 (dd, J= 8.6 Hz, 10.9 Hz 5H), 7.41

(t, J= 8.3Hz, 5H), 4.47 (t, J= 9.2 Hz, 2H), 3.32 (t, J= 8.5 Hz, 2H).
13

C NMR (75.6 MHz, CD2Cl2) δ (ppm): 173.9, 156.0, 139.0, 136.7, 129.7, 129.1, 128.6,

128.2, 125.4, 124.4, 48.6, 32.0.
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 129.1, 128.6, 128.2, 125.4, 124.4; (-) 48.7,
32.1.
IR (neat, cm-1): 3285.4, 1595.3, 1513.6, 1449.7, 1412.8, 1349.8, 1226.1, 1086.2, 993.3,
834.7, 761.5, 667.5.
Melting Point Range: 145- 147°C
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Compound 2

Synthesis of 3-(4-chlorophenyl)-N-phenyl-1H-pyrazole-1-carbothiamide:
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (0.025 g, 0.079 mmol, 1 equiv.) and an
iodine crystal (0.0373 g, 0.147 mmol) was dissolved in 0.50 mL of DMSO.18 This solution
was refluxed for 2 hours before cooling to ambient temperature. A thick paste resulted on
the glass with an orange-brown liquid supernatant. The liquid resulting was decanted and
the solid was washed twice with aqueous 10% sodium thiosulfate. The washes were
combined with the decanted liquid. Ethanol (2 mL) was added with two drops of 0.60 M
acetic acid resulting in the precipitation of black solid. The supernatant was decanted, and
a small quantity of ice was added to the supernatant which induced immediate
precipitation.
This compound was not fully characterized and has not been screened for ADH inhibition.

IR (neat, cm-1): 3286.0, 3038.3, 1595.5, 1514.1, 1327.0, 834.8, 761.4, 692.0.
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Compound 3

Synthesis of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-phenyl-4,5-dihydro-1H-pyrazole (1.43 g, 9.82 mmol, 1.00 equiv.) was dissolved in 25.0
mL anhydrous ether with three drops of triethylamine and phenyl isocyanate (1.00 mL,
9.82 mmol, 1.00 equiv.) phenyl isocyanate. This solution stirred for three days at room
temperature and the solid orange product was filtered and dried, in 39.0% yield.

1

H NMR (300 MHz, dmso-d6) δ (ppm): 8.91 (s, 1H), 8.61 (s, 6H), 7.86 (dd, J= 2.9 Hz, 8.6

Hz, 2H), 7.62 (dd, J= 1.2Hz, 7.3 Hz, 2H), 7.44 (dd, J= 1.4 Hz, 8.8 Hz, 16H), 7.24 (t, J=
8.5 Hz, 15H), 6.93 (tt, J= 1.2 Hz, 7.3 Hz, 8H), 3.91(t, J= 10.0 Hz, 2H), 3.28 (t, J= 10.1 Hz,
4H, overlap with H2O impurity at 3.33 ppm). Aromatic impurity observed in spectrum.
13

C NMR (75.6 MHz, CD2Cl2) δ (ppm): 153.7, 152.1, 139.0, 131.6, 130.1, 129.3, 128.9,

128.7, 128.7, 128.5, 126.7, 126.5, 126.2, 122.7, 119.3, 118.9, 44.5, 32.5.
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 120.1, 128.9, 128.7, 126.7, 126.5, 126.2,
122.7, 118.9; (-) 44.5, 32.5.
IR (neat, cm-1): 3390.8, 3348.4, 2949.0, 1671.8, 1591.4, 1532.6, 1444.1, 1309.0, 746.7,
687.0.
Melting Point Range: 142.4- 153.6°C
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Compound 6

Synthesis of 1-(3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)butan-1-one:
A solution of 3-phenyl-4,5-dihydro-1H-pyrazole (1.58 g, 12.5 mmol, 1 equiv.) in 50.0 mL
chloroform was chilled on ice before the addition of triethylamine (1.26 mL, 12.5 mmol,
1.00 equiv.) followed by butyric anhydride (2.00 mL, 12.5 mmol, 1.00 equiv.). This
solution was warmed to room temperature and stirred for three hours. White solid
precipitate was washed and dried, in 76.3% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (m, J= 2.6Hz, 2H), 7.43 (m, J= 2.2Hz, 3H),

2.61 (t, J= 7.5Hz, 2H), 1.57 (m, J= 7.4Hz, 2H), 0.90 (t, J= 7.4Hz, 3H)
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 170.7, 156.5, 130.9, 130.7, 129.3, 127.0, 44.5,

35.7, 31.8, 18.5, 14.4.
IR (neat, cm-1): 3055.3, 2957.2, 1625.5, 1412.1, 1319.5, 1152.8, 1040.6, 848.4, 756.5,
690.5, 582.8.
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Compound 9

Synthesis of 3‐(4‐chlorophenyl)‐N‐methyl‐N‐propyl‐4,5‐dihydro‐1H‐pyrazole‐1‐
carboxamide:
3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole-carboxamide 8 (0.020 g, 0.08
mmol, 1.00 equiv.) was dissolved in 0.40 mL THF, anhydrous under nitrogen. Sodium
hydride (60%) (0.010 g, 0.23 mmol, 3.00 equiv.) was added to the solution and stirred
one hour on ice. Methyl iodide (10.0 L, 0.080 mmol, 1.00 equiv.) was added to the
stirring solution dropwise and stirred. The reaction was monitored by TLC with a 50.%
ethyl acetate: hexanes mobile phase. After two hours the solution was cooled on ice and
an additional equivalent of NaH was added followed by an additional 1.50 equivalents
(15.0 L) of methyl iodide. After another four hours an additional equivalent of methyl
iodide (10.0 L) was added. After another 24 hours stirring at room temperature under
nitrogen, ice was added to the solution and the resulting precipitate was filtered. The
resulting yellow oil and solid white precipitate was isolated as an off-white solid (6.3 mg,
29% yield) following purification (12-52% ethyl acetate: hexanes, silica gel column
chromatography). Recovered 15.6 mg of 3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1Hpyrazole-carboxamide 8.

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.58 (d, J= 8.3Hz, 2H), 7.37 (d, J= 8.5Hz, 2H), 3.96

(t, J= 9.7Hz, 2H), 3.39 (t, J= 7.7Hz, 2H), 3.02 (t, J= 10.1Hz, 4H), 1.69 (m, J= 7.5Hz, 3H),
0.92 (t, J= 7.5Hz, 3H).
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13

C NMR (75.6 MHz, CDCl3) δ (ppm): 151.2, 135.3, 131.0, 128.9, 127.4, 21.2. (Missing

signals are observed in DEPT-135 spectra).
DEPT-135 (75.6 MHz, CDCl3) δ (ppm): (+) 128.9, 127.4, 56.3, 36.6, 11.3; (-) 52.6, 47.3,
30.6, 21.2.
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Compound 11

Synthesis of (1Z)‐1‐(methylsulfanyl)‐N‐propy1‐(3‐phenyl‐4,5‐dihydro-1H-pyrazol-1-yl)
methanimine:
3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole carbothiamide 10 (0.030 g, 0.09
mmol, 1.00 equiv.) was dissolved in 1 mL CH2Cl2. This solution was chilled on ice before
the gradual addition of methyl iodide (0.32 g, 2.3 mmol, 25 equiv.). This stirring solution
was warmed to room temperature and stirred at ambient temperature for 68 hours. The
reaction was monitored by TLC with a 4:1 hexanes: ethyl acetate mobile phase. This
solution was concentrated under reduced pressure, reconstituted in CH2Cl2, and washed
with 10% NaOH. The organic layer was dried over MgSO4, filtered, and concentrated to
yield a yellow viscous oil. This oil was purified to yield 11 as a white solid (21.6 mg,
81%).

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.63 (d, J= 6.6Hz, 2H), 7.33 (d, J= 6.8Hz, 2H),

3.96 (t, J= 10.2, 2H), 3.48 (t, J= 7.1, 2H), 3.08 (t, J= 10.0Hz, 2H), 2.53 (s, 3H), 1.58 (m,
J= 7.2Hz, 3H), 0.94 (t, J= 7.4Hz, 3H)
13

C NMR (75.6 MHz, CDCl3) δ (ppm): 150.9, 135.0, 128.9, 127.2, 53.6, 48.4, 31.2, 25.0,

16.9, 12.0.
DEPT-135 (75.6 MHz, CDCl3) δ (ppm): (+) 128.9, 127.2, 29.5, 16.9, 12.0; (-) 53.6, 48.4,
31.2, 25.0.
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Compound 12

Synthesis of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide:
3-phenyl-4,5-dihydro-1H-pyrazole (2.58 g, 17.6 mmol, 1.00 equiv.) was dissolved in 47
mL anhydrous ether with three drops of triethylamine and phenyl isothiocyanate (1.00 mL,
16.9 mmol, 1.00 equiv.) phenyl isothiocyanate. This solution stirred for 1.5 hours at room
temperature and the solid yellow product was filtered and dried, 54.5% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 9.13 (bs, 1H), 7.76 (dd, J= 2.1 Hz, 6.2 Hz, 2H),

7.65 (d, J= 7.9 Hz, 2H), 7.46 (t, J= 1.9 Hz, 3H), 7.38 (t, J= 7.6 Hz, 2H), 7.21 (t, J= 7.9 Hz,
1H), 4.46 (t, J= 10.3 Hz, 2H), 3.34 (t, J= 10.2 Hz, 2H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 157.0, 138.8, 131.0, 129.0, 128.8, 126.9, 125.7,

124.6, 48.5, 32.2.
IR (neat, cm-1): 3335.0, 3050.9, 1588.1, 1516.2, 1343.6, 760.6, 688.5.
Melting Point Range: 158.4- 159.4°C

90

91

92

93

Compound 13

Synthesis of 3-(4-chlorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (1.58 g, 9.66 mmol, 1.00 equiv.) was
dissolved in 50.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate
(2.11 g, 9.66 mmol, 1.00 equiv.). The solution stirred for 1.5 hours at room temperature
and yellow crystalline solid was filtered and dried, in 40.0% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm):7.98 (bs, 1H), 7.66 (dd, J= 4.7 Hz, 2.9Hz, 2H), 7.54

(d, J= 7.5Hz, 2H), 7.41 (dt, J= 4.7Hz, 2.0Hz, 2H), 7.32 (td, J= 6.1Hz, 2.1, 2H), 7.05 (t, J=
7.4Hz, 1H), 4.11 (t, J= 9Hz, 2H), 3.27 (t, J= 9Hz, 2H).
13

C NMR (75.6 MHz, CDCl3) δ (ppm): 152.5, 152.1, 138.5, 136.2, 129.9, 129.3, 129.1,

127.7, 123.2, 120.7, 119.2, 44.6, 32.5.
IR (neat, cm-1): 3284.0, 3036.0, 1647.10, 1592.6, 1532.8, 1496.7, 1314.3, 1231.2, 741.4,
684.6.
Melting Point Range: 143- 148°C

94

95

96

97

Compound 14

Synthesis of 3-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (1.37 g, 7.80 mmol, 1.00 equiv.) was
dissolved in 50.0 mL dry ether with three drops of triethylamine and phenyl isocyanate
(0.85 mL, 7.80 mmol, 1.00 equiv.). This solution stirred for two hours at room temperature
and yellow solid product was filtered and dried, in 32.0% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 8.01 (bs, 1H), 7.68 (d, J= 9.0 Hz, 2H), 7.54 (dd, J=

1.2 Hz, 8.7 Hz, 2H), 7.32 (tt, J= 1.2 Hz, 7.3 Hz, 2H), 7.04 (t, J= 9 Hz, 2H), 6.95 (d, J= 8.9
Hz, 2H), 4.07 (t, J=9.9 Hz, 2H), 3.87 (s, 3H), 3.27 (t, J= 9.9 Hz, 2H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 161.2, 154.1, 152.1, 140.0, 129.0, 128.9, 124.6,

122.6, 119.8, 114.5, 55.9, 45.0, 32.3.
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 128.9, 122.6, 119.8, 114.5, 55.9; (-) 45.0,
32.3
IR (neat, cm-1): 3348.6, 2961.4, 1658.7, 1591.9, 1418.1, 1169.6, 878.8, 687.3, 583.7.
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Compound 15

Synthesis of N-phenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-(4-methylphenyl-4,5-dihydro-1H-pyrazole (0.92 g, 5.77 mmol, 1.00 equiv.) was
dissolved in 40.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate
(0.70 mL, 5.77 mmol, 1.00 equiv.). The solution stirred for two hours at room temperature
and sand colored solid/paste was filtered and dried, in 58.0% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 8.03 (bs, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.54 (dd, J=

1.8 Hz, J= 7.6 Hz, 2H), 7.31 (t, J=7.5 Hz, 5H, overlap with CHCl3 solvent impurity peak),
7.05 (t, J= 8.7 Hz, 1H), 4.08 (t, J=10.5 Hz, 2H), 3.28 (t, J=10.2 Hz, 2H), 2.41 (s, 3H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 154.3, 152.5, 140.2, 140.0, 129.6, 129.3, 129.0,

127.3, 122.7, 119.8, 114.4, 45.1, 32.2, 21.6.
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 129.7, 129.0, 127.3, 122.7, 119.8, 21.6; (-)
45.1, 32.2.
IR (neat, cm-1): 3426.2, 1665.1, 1591.0, 1497.8, 1427.1, 1237.1, 742.8, 687.0, 563.3.
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Compound 16

Synthesis of 3‐(4‐fluorophenyl)‐N‐phenyl‐4,5‐dihydro‐1H‐pyrazole-1-carboxamide:
3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (2.35 g, 14.3 mmol, 1.00 equiv.) was
dissolved in 45.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate
(1.80 mL, 14.3 mmol, 1.00 equiv.). This solution stirred for one hour at room temperature
and the pale-yellow solid was filtered and dried, in 97.0% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.98 (bs, 1H), 7.72 (td, J= 5.3, 2.2Hz, 2H), 7.54 (dd,

J= 7.6, 1.0Hz, 2H), 7.32 (t, J= 8.4Hz, 2H), 7.13 (t, J= 8.4Hz, 1H), 7.05 (t, J= 7.3Hz, 1H),
4.11 (t, J= 9.6Hz, 2H), 3.28 (t, J= 10.0Hz, 2H).
13

C NMR (75.6 MHz, CD2Cl2) δ (ppm): 165.5, 162.2, 152.7, 152.0, 138.9, 128.9, 128.4,

128.0, 127.9, 122.8, 118.9, 115.9, 115.6, 44.6, 32.6.
DEPT-135 (75.6 MHz, CD2Cl2)) δ (ppm): (+) 128.9, 128.5, 128.4, 122.8, 118.9, 115.9,
115.6; (-) 44.6, 32.6.
IR (neat, cm-1): 3393.9, 1664.5, 1593.8, 1534.9, 1446.6, 1223.1, 838.3, 814.2, 742.6, 685.8,
581.5.
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Compound 17

Synthesis of 3-methyl-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-methyl-4,5-dihydro-1H-pyrazole (176 mmol, 14.8g, 2.80 equiv.) was re-dissolved in
50.0 mL anhydrous ether. Five drops triethylamine was added with phenyl isocyanate (61.2
mmol, 8.00 mL, 1.00 equiv.) and stirred at room temperature for 1.5 hours. The resulting
taupe-colored solid was filtered and dried, in 69% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 9.12 (bs, 1H), 7.77 (dd, J= 4.5, 1.7Hz, 2H), 7.64 (d,

J= 7.9Hz, 2H), 7.46 (dd, J= 1.9, 4.1Hz, 2H), 7.39 (t, J= 8.3Hz, 2H), 7.21 (t, J= 7.3Hz,
1H), 4.47 (t, J= 10.3Hz, 2H), 3.35 (t, J= 9.7Hz, 2H)
IR (neat, cm-1): 3276.7, 3050.8, 1645.6, 1592.8, 1546.0, 1439.6, 1293.2, 1230.1, 751.9,
694.9.
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Compound 18

Synthesis of 3-phenyl-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-phenyl-4,5-dihydro-1H-pyrazole (2.00 g, 13.7 mmol, 1.00 equiv.) was dissolved in 50.0
mL anhydrous ether with three drops of triethylamine and propyl isocyanate (1.28 mL,
13.7 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the
orange prude product was purified via silica flash column with a 30- 100% ethyl acetate:
hexanes gradient, in 39.2% yield.

1

H NMR (300 MHz, dmso-d6) δ (ppm): 7.68 (dd, J= 5.6, 2.4Hz, 2H), 7.40 (m, J= 6Hz,

3H), 6.9120 (t, J= 5.9 Hz, 1 H), 4.01 (t, J= 10.6Hz, 2H), 3.17 (t, J= 10.6Hz, 2H), 3.04 (q,
J= 6.1, 2H) 1.43 (m, J= 7.2Hz, 2H), 0.84 (t, J= 7.5Hz, 3H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.4, 152.9, 130.3, 130.0, 129.1, 126.8, 45.4,

41.8, 32.0, 23.8, 11.8.
IR (neat, cm-1): 3353.4, 2871.6, 1637.6, 1517.6, 1256.8, 1130.1, 858.2, 757.1, 694.5.
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Compound 19

Synthesis of 3-phenyl-N-propyl-4,5-dihydro-1H-pyrazole-1-carbothioamide:
3-phenyl-4,5-dihydro-1H-pyrazole (2.17 g, 14.8 mmol, 1.00 equiv.) was dissolved in 50.0
mL anhydrous ether with 3 drops of triethylamine and propyl isocyanate (1.50 mL, 14.8
mmol, 1.00 equiv.). This solution stirred for three days at room temperature and ice was
added to the red liquid product. Crystals formed along the phase boundary were isolated
and dried via vacuum filtration. Compound 19 was isolated as a crystalline solid (0.25 g,
6.9% yield) following purification via gradient silica flash column chromatography (30100% ethyl acetate: hexanes).

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (dd, J= 3.9, 2.1Hz, 2H), 7.43 (dd, J= 2.1, 2.3Hz,

3H), 4.38 (t, J= 9.8Hz, 2H), 3.64 (q, J= 5.9, 2H), 3.26 (t, J= 9.8Hz, 2H), 1.71 (m, J= 7.3Hz,
2H), 1.0 (t, J= 7.4Hz, 3H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 175.6, 156.8, 131.8, 130.8, 129.2, 127.4, 49.3,

46.2, 31.6, 22.7, 11.8.
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.8, 129.2, 127.4, 11.8; (-) 49.3, 46.2,
31.7, 22.7.
IR (neat, cm-1): 3349.1, 2966.0, 1689.5, 1589.3, 1520.0, 1385.3, 1175.1, 752.0, 687.9,
626.9.
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Compound 20

Synthesis of N-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-phenyl-4,5-dihydro-1H-pyrazole (1.51 g, 12.0 mmol, 1.00 equiv.) was dissolved in 40.0
mL dry ether with three drops triethylamine and p-methoxyphenyl isocyanate (1.79 g, 12.0
mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the
resulting peach solid was filtered and dried, in 93.8% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (t, J= 3.8Hz, 2H), 7.45 (dd, J= 5.4Hz, 2.2Hz,

3H), 6.87 (dd, J= 8.7, 1.6Hz, 2H), 4.09 (t, J= 9.3Hz, 2H), 3.79 (s, 3H), 3.31 (t, J= 10.5Hz,
2H).
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.25, 153.9, 152.8, 132.9, 132.1, 130.3, 129.1,

127.2, 121.8, 114.2, 55.7, 45.3, 32.1.
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.3, 129.1, 127.2, 121.8, 114.2, 55.7; (-)
45.3, 32.1.

IR (neat, cm-1): 3392.0, 2958.1, 1657.7, 1594.9, 1535.8, 1419.8, 1240.8, 1099.9, 1032.4,
815.3, 688.2, 575.2.
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Compound 21

Synthesis of N-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-phenyl-4,5-dihydro-1H-pyrazole (1.51g, 12.0 mmol, 1.00 equiv.) was dissolved in 40.0
mL anhydrous ether with three drops triethylamine and 4-chlorophenyl isocyanate (1.84 g,
12.0 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the
peach solid product was filtered and dried, in 94.0% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 7.99 (bs, 1H), 7.67 (dd, J= 3.4, 1.9Hz, 2H), 7.53 (d,

J= 8.9Hz, 2H), 7.41 (t, J= 2.4Hz, 3H), 7.32 (q, J= 9Hz, 3H), 4.11 (t, J= 12Hz, 2H), 3.27
(t, J= 9.1Hz, 2H).
13

C NMR (75.6 MHz, CD2Cl2) δ (ppm): 154.0, 137.7, 131.4, 130.2, 128.8, 128.7, 126.5,

120.1, 100.0, 44.4, 32.5.
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 130.2, 128.8, 128.7, 126.5, 120.1; (-) 44.4,
32.5.
IR (neat, cm-1): 3383.0, 2887.6, 1690.7, 1590.0, 1530.9, 1339.4, 822.4, 683.2, 601.7.
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Compound 22

Synthesis of N-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide:
3-phenyl-4,5-dihydro-1H-pyrazole (1.51 g, 12.0 mmol, 1 equiv.) was dissolved in 40.0 mL
anhydrous ether and three drops of triethylamine with p-nitrophenyl isocyanate (1.97 g,
12.0 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the
resulting brown solid was filtered and dried, in 83.2% yield.

1

H NMR (300 MHz, CDCl3) δ (ppm): 8.22 (d, J= 9.3Hz, 2H), 7.73 (m, J= 9.0Hz, 3H), 7.47

(t, J= 6.0Hz, 3H), 4.12 (t, J= 9.8Hz, 2H), 3.34 (t, J= 9.9Hz, 2H)
13

C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.4, 151.7, 146.9, 141.7, 131.8, 130.7, 129.1,

127.4, 125.3, 119.0, 45.2, 32.3.
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.7, 129.1, 127.4, 125.3, 119.0; (-) 45.2,
32.3.
IR (neat, cm-1): 3357.7, 3069.6, 1681.5, 1596.9, 1530.2, 1490.9, 1328.4, 1235.1, 1111.5,
1086.0, 852.6, 750.5, 690.9.
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Compound 26

Synthesis of phenyl (3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone:
3-phenyl-4,5-dihydro-1H-pyrazole (0.92 g, 6.26 mmol, 1.00 equiv.) in 50.0 mL chloroform
was chilled on ice before the addition of triethylamine (0.65 mL, 6.26 mmol, 1.00 equiv.)
followed by benzoic anhydride (1.42 g, 6.26 mmol, 1.00 equiv.). This solution was warmed
to room temperature and stirred for three hours, the resulting white solid precipitate was
vacuum filtered and dried, in 85.4% yield.

This compound was not fully characterized and has not been screened for ADH inhibition.

IR (neat, cm-1): 3199.1, 3001.1, 1665.5, 1628.7, 1486.7, 1284.8, 1028.1, 868.8, 703.7.
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Supplemental Information B
Horse Liver Alcohol Dehydrogenase FASTA Sequence (1HLD)31
Highlighted region indicates the substrate binding region of the active site. These
residues (residues 49-67) are interacting with the substrate/positioned compound 1 as
indicated by AutoDock analysis. Pink highlighted regions indicate charged residues.
Green regions indicate nonpolar residues and yellow regions indicate polar residues.
>1HLD:A|PDBID|CHAIN|SEQUENCE
STAGKVIKCKAAVLWEEKKPFSIEEVEVAPPKAHEVRIKMVATGICRSDDHVVS
GTLVTPLPVIAGHEAAGIVESIGEGV
TTVRPGDKVIPLFTPQCGKCRVCKHPEGNFCLKNDLSMPRGTMQDGTSRFTCRG
KPIHHFLGTSTFSQYTVVDEISVAKI
DAASPLEKVCLIGCGFSTGYGSAVKVAKVTQGSTCAVFGLGGVGLSVIMGCKAA
GAARIIGVDINKDKFAKAKEVGATEC
VNPQDYKKPIQEVLTEMSNGGVDFSFEVIGRLDTMVTALSCCQEAYGVSVIVGV
PPDSQNLSMNPMLLLSGRTWKGAIFG
GFKSKDSVPKLVADFMAKKFALDPLITHVLPFEKINEGFDLLRSGESIRTILTF
>1HLD:B|PDBID|CHAIN|SEQUENCE
STAGKVIKCKAAVLWEEKKPFSIEEVEVAPPKAHEVRIKMVATGICRSDDHVVS
GTLVTPLPVIAGHEAAGIVESIGEGV
TTVRPGDKVIPLFTPQCGKCRVCKHPEGNFCLKNDLSMPRGTMQDGTSRFTCRG
KPIHHFLGTSTFSQYTVVDEISVAKI
DAASPLEKVCLIGCGFSTGYGSAVKVAKVTQGSTCAVFGLGGVGLSVIMGCKAA
GAARIIGVDINKDKFAKAKEVGATEC
VNPQDYKKPIQEVLTEMSNGGVDFSFEVIGRLDTMVTALSCCQEAYGVSVIVGV
PPDSQNLSMNPMLLLSGRTWKGAIFG
GFKSKDSVPKLVADFMAKKFALDPLITHVL PFEKINEGFDLLRSGESIRTILTF

142

